Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 12, 2005, Pages 3955-3965

  Flores Borja, Fabian ^a   Kabouridis, Panagiotis S ^a   Jury, Elizabeth C ^b   Isenberg, David A ^b   Mageed, Rizgar A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CBL PROTEIN; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; INTERLEUKIN 10; PROTEIN KINASE LYN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD SAMPLING; CONFOCAL MICROSCOPY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UBIQUITINATION; ULTRACENTRIFUGATION;

ADULT; AGED; B-LYMPHOCYTES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE MICRODOMAINS; MIDDLE AGED; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; UBIQUITIN;

EID: 29144478403     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21416     Document Type: Article

References (41)

1. Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 1999;20:119-24.
2. Tanaka Y, Shirakawa F, Ota T, Suzuki H, Eto S, Yamashita U. Mechanism of spontaneous activation of B cells in patients with systemic lupus erythematosus: analysis with anti-class II antibody. J Immunol 1988;140:761-7.
3. Mageed RA, Prud'homme G. Immunopathology and the gene therapy of lupus. Gene Ther 2003;10:861-73.
4. Reininger L, Winkler T, Kalberer CP, Jourdan M, Melchers F, Rolink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW)F1 mice. J Exp Med 1996;184:853-61.
5. O'Keefe TL, Williams GT, Batista F, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-13.
6. Pritchard NR, Cutler A, Uribe S, Chadban S, Morley B, Smith KG. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr Biol 2000;10:227-30.
7. Pan C, Bamgarth N, Parnes JR. CD72-deficient mice reveal non-redundant roles of CD72 in B cell development and activation. Immunity 1999;11:495-506.
8. Salmon JE, Millard S, Schachter L, Arnett F, Ginzler EM, Gourley M, et al. FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
9. Hatta Y, Tsuchiya N, Matsushita M, Shiota M, Hagiwara K, Tokunaga K. Identification of the gene variations in human CD22. Immunogenetics 1999;49:280-6.
10. Kurosaki T. Molecular dissection of B cell antigen receptor signaling. Int J Mol Med 1998;1:515-27.
11. Pao LI, Famiglietti S, Cambier JC. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction. J Immunol 1998;160:3305-14.
12. Cornall R, Cyster J, Hibbs M, Dunn A, Otipoby K, Clark A, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
13. De Franco AL. The complexity of signaling pathways activated by the BCR. Curr Opin Immunol 1997;9:296-308.
14. Ma H, Yankee T, Hu J, Asai D, Harrison M, Geahlen RL. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J Immunol 2001;166:1507-16.
15. Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002;196:1593-604.
16. Liossis SN, Solomou E, Dimopoulos M, Panayiotidis P, Mavrikakis M, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 2001;49:157-65.
17. Huck S, le Corre R, Youinou P, Zouali M. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 2001;33:213-24.
18. Cheng PC, Dykstra M, Mitchell R, Pierce SK. A role for lipid rafts in BCR signaling and antigen targeting. J Exp Med 1999;190:1549-60.
19. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72.
20. Hay EM, Bacon P, Gordon C, Isenberg DA, Madison P, Snaith M, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
22. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
23. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
24. Brdicka T, Imrich M, Angelisova P, Brdickova N, Horvath O, Spicka J, et al. Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling. J Exp Med 2002;196:1617-26.
25. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996;384:484-9.
26. Hakak Y, Martin GS. Ubiquitin-dependent degradation of active Src. Curr Biol 1999;9:1039-42.
27. Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 1999;96:9557-62.
28. high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
29. DeFranco AL, Chan VW, Lowell CA. Positive and negative roles of the tyrosine kinase Lyn in B cell function. Semin Immunol 1998;10:299-307.
30. Shao Y, Yang C, Elly C, Liu YC. Differential regulation of the B cell receptor-mediated signaling by the E3 ubiquitin ligase Cbl. J Biol Chem 2004;279:43646-53.
31. Rao N, Miyake S, Reddi AL, Douillard P, Ghosh AK, Dodge IL, et al. Negative regulation of Lck by Cbl ubiquitin ligase. Proc Natl Acad Sci U S A 2002;99:3794-9.
32. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
33. Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1343-54.
34. Nambiar MP, Enyedy E, Fisher CU, Krishnan S, Warke VG, Gilliland WR, et al. Abnormal expression of various molecular forms and distribution of T cell receptor ζ chain in patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:163-74.
35. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001;2:294-307.
36. Kyo S, Sada K, Qu X, Maeno K, Miah SM, Kawauchi-Kamata K, et al. Negative regulation of Lyn protein-tyrosine kinase by c-Cbl ubiquitin-protein ligase in FcγRI-mediated mast cell activation. Genes Cells 2003;8:825-36.
37. Winberg G, Matskova L, Chen F, Plant P, Rotin D, Gish G, et al. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol Cell Biol 2000;20:8526-35.
38. Grolleau A, Kaplan MJ, Hanash SM, Beretta L, Richardson B. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 2000;106:1561-8.
39. Khan IU, Laxminarayana D, Kammer GM. Protein kinase A RI β subunit deficiency in lupus T lymphocytes: bypassing a block in RI β translation reconstitutes protein kinase A activity and augments IL-2 production. J Immunol 2001;166:7600-5.
40. Smith KG, Tarlinton D, Doody G, Hibbs M, Fearon D. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med 1998;187:807-11.
41. Aman MJ, Tosello-Trampont A, Ravichandran K. FcγRIIB1/ SHIP-mediated inhibitory signaling in B cells involves lipid rafts. J Biol Chem 2001;279:46371-8.